Non-medical opioid use, harms, and interventions in Canada – a 10-year update on an unprecedented substance use-related public health crisis

References

• Arkell, C. (2018). Harm reduction in action: Supervised consumption services and overdose prevention sites. Prevention in Focus. Retrieved from www.catie.ca/en/pif/fall-2018/harm-reduction-action-supervised-consumption-services-and-overdose-prevention-sites
   Google Scholar
• BC Office of the Provincial Health Officer. (2019). Stopping the harm: Decriminalization of people who use drugs in BC. Vancouver, BC: BC Officer of the Provincial Health Officer. Retrieved from https://www2.gov.bc.ca/assets/gov/health/about-bc-s-health-care-system/office-of-the-provincial-health-officer/reports-publications/special-reports/stopping-the-harm-report.pdf
   Google Scholar
• Belzak, L., & Halverson, J. (2018). The opioid crisis in Canada: A national perspective. Health Promotion & Chronic Disease Prevention in Canada: Research, Policy & Practice, 38, 224–233. doi:10.24095/hpcdp.38.6.02
   PubMed Web of Science ®Google Scholar
• Bruneau, J., Ahamad, K., Goyer, M.È., Poulin, G., Selby, P., Fischer, B., … Wood, E. (2018). Management of opioid use disorders: A national clinical practice guidelines. Canadian Medical Association Journal, 190, E247–E257. doi:10.1503/cmaj.170958
   PubMed Web of Science ®Google Scholar
• Busse, J.W., Craigie, S., Juurlink, D.N., Buckley, D.N., Wang, L., Couban, R.J., … Guyatt, G.H. (2017). Guideline for opioid therapy and chronic noncancer pain. Canadian Medical Association Journal, 189, E659–E666. doi:10.1503/cmaj.170363
   PubMed Web of Science ®Google Scholar
• Canadian Institutes for Health Information. (2016). Hospitalizations and emergency department visits due to opioid poisoning in Canada. Ottawa, ON: Canadian Institutes for Health Information (CIHI).
   Google Scholar
• Canadian Institutes for Health Information. (2017). Pan-Canadian trends in the prescribing of opioids, 2012 to 2016. Ottawa, ON: Canadian Institutes for Health Information (CIHI).
   Google Scholar
• Canadian Institutes for Health Information. (2018). Table 1: Number and crude rate per 100,000 population of opioid poisoning hospitalizations by diagnosis type and fiscal year, Canada, 2007–2008 to 2016–2017. Ottawa, ON: Canadian Institutes for Health Information (CIHI).
   Google Scholar
• Canadian Pharmacists Association. (2017). Environmental scan: Access to naloxone across Canada. Toronto, ON: Canadian Pharmacists Association (CPA). Retrieved form https://www.pharmacists.ca/cpha-ca/assets/File/cpha-on-the-issues/Environmental%20Scan%20-%20Access%20to%20Naloxone%20Across%20Canada_Final.pdf
   Google Scholar
• Case, A., & Deaton, A. (2015). Rising morbidity and mortality in midlife among white non-Hispanic Americans in the 21st century. Proceedings of the National Academy of Sciences, 112, 15078–15083. doi:10.1073/pnas.1518393112
   PubMed Web of Science ®Google Scholar
• CBC News. (2019). ‘Safe supply’ program will distribute free opioids to entrenched users. British Columbia. Retrieved form https://www.cbc.ca/news/canada/british-columbia/phs-injectable-dilaudid-program-launching-1.4965641
   Google Scholar
• Cressman, A.M., Mazereeuw, G., Guan, Q., Jia, W., Gomes, T., & Juurlink, D.N. (2017). Availability of naloxone in Canadian pharmacies: A population-based survey. CMAJ Open, 5, E779. doi:10.9778/cmajo.2017012 doi:10.9778/cmajo.20170123
   PubMedGoogle Scholar
• Dhalla, I.A., Persaud, N., & Juurlink, D.N. (2011). Facing up to the prescription opioid crisis. BMJ, 343, d5142. doi:bmj.d5142/bmj.d5142
   PubMedGoogle Scholar
• Dowell, D., Haegerich, T.M., & Chou, R. (2016). CDC guideline for prescribing opioids for chronic pain—United States, 2016. JAMA, 315, 1624–1645. doi:10.1001/jama.2016.1464
   PubMed Web of Science ®Google Scholar
• Fairbairn, N., Coffin, P.O., & Walley, A.Y. (2017). Naloxone for heroin, prescription opioid, and illicitly made fentanyl overdoses: Challenges and innovations responding to a dynamic epidemic. International Journal of Drug Policy, 46, 172–179. doi:10.1016/j.drugpo.2017.06.005
   PubMed Web of Science ®Google Scholar
• Fischer, B., Goldman, B., Rehm, J., & Popova, S. (2008). Non-medical use of prescription opioids and public health in Canada. Canadian Journal of Public Health, 99, 182–184. doi:10.17269/cjph.105.4143
   PubMed Web of Science ®Google Scholar
• Fischer, B., Gooch, J., Goldman, B., Kurdyak, P., & Rehm, J. (2014). Non-medical prescription opioid use, prescription opioid-related harms and public health in Canada: An update 5 years later. Canadian Journal of Public Health, 105, e146–149. doi:10.17269/cjph.105.4143
   PubMed Web of Science ®Google Scholar
• Fischer, B., Jones, W., Urbanoski, K., Skinner, R., & Rehm, J. (2014). Correlations between prescription opioid analgesic dispensing levels and related mortality and morbidity in Ontario, Canada, 2005–2011. Drug and Alcohol Review, 33, 19–26. doi:10.1111/dar.12089
   PubMed Web of Science ®Google Scholar
• Fischer, B., Jones, W., Vojtila, L., & Kurdyak, P. (2018). Patterns, changes, and trends in prescription opioid dispensing in Canada, 2005–2016. Pain Physician, 21(3), 219–228. Retrieved from https://www.painphysicianjournal.com/current/abstracts?article=NTIwMg%3D%3D&journal=111
   PubMed Web of Science ®Google Scholar
• Fischer, B., Kurdyak, P., Goldner, E., Tyndall, M., & Rehm, J. (2016). Treatment of prescription opioid disorder in Canada: Looking at the ‘other epidemic’? Substance Abuse Treatment, Prevention, and Policy, 11, 12. doi:10.1186/s13011-016-0055-4
   PubMed Web of Science ®Google Scholar
• Fischer, B., Pang, M., & Tyndall, M. (2019). The opioid death crisis in Canada: Crucial lessons for public health. The Lancet Public Health, 4, e81–e82. doi:10.1016/S2468-2667(18)30232-9
   PubMed Web of Science ®Google Scholar
• Fischer, B., Rehm, J., & Tyndall, M. (2016). Effective Canadian policy to reduce harms from prescription opioids: Learning from past failures. CMAJ, 188, 1240–1244. doi:10.1503/cmaj.160356
   PubMed Web of Science ®Google Scholar
• Fischer, B., Varatharajan, T., Shield, K., Rehm, J., & Jones, W. (2018). Crude estimates of prescription opioid-related misuse and use disorder populations towards informing intervention system need in Canada. Drug and Alcohol Dependence, 189, 76–79. doi:10.1016/j.drugalcdep.2018.04.024
   PubMed Web of Science ®Google Scholar
• Fischer, B., Vojtila, L., & Kurdyak, P. (2017). ‘Delisting’OxyContin® to reduce prescription opioid‐related harms in Ontario (Canada)—gauging effects 5 years later. Pharmacoepidemiology and Drug Safety, 26, 1040–1043. doi:10.1002/pds.4253
   PubMed Web of Science ®Google Scholar
• Fischer, B., Vojtila, L., & Rehm, J. (2018). The ‘fentanyl epidemic’in Canada–Some cautionary observations focusing on opioid-related mortality. Preventive Medicine, 107, 109–113. doi:10.1016/j.ypmed.2017.11.001
   PubMed Web of Science ®Google Scholar
• Furlan, A.D., MacDougall, P., Pellerin, D., Shaw, K., Spitzig, D., Wilson, G., & Wright, J. (2014). Overview of four prescription monitoring/review programs in Canada. Pain Research Management, 19, 102–106. doi:10.1155/2014/634171
   PubMed Web of Science ®Google Scholar
• Gomes, T., Greaves, S., Tadrous, M., Mamdani, M.M., Paterson, J.M., & Juurlink, D.N. (2018). Measuring the burden of opioid-related mortality in Ontario, Canada. Journal of Addiction Medicine, 12, 418. doi:10.1097/ADM.0000000000000412
   PubMed Web of Science ®Google Scholar
• Gomes, T., Juurlink, D., Yao, Z., Camacho, X., Paterson, J.M., Singh, S., … Mamdani, M. (2014). Impact of legislation and a prescription monitoring program on the prevalence of potentially inappropriate prescriptions for monitored drugs in Ontario: A time series analysis. CMAJ Open, 2, E256. doi:10.9778/cmajo.20140027
   PubMedGoogle Scholar
• Gomes, T., Khuu, W., Martins, D., Tadrous, M., Mamdani, M.M., Paterson, J.M., & Juurlink, D.N. (2018). Contributions of prescribed and non-prescribed opioids to opioid related deaths: Population based cohort study in Ontario, Canada. BMJ, 362, k3207. doi:bmj.k3207/bmj.k3207
   PubMedGoogle Scholar
• Gomes, T., Mamdani, M.M., Dhalla, I.A., Cornish, S., Paterson, J.M., & Juurlink, D.N. (2014). The burden of premature opioid-related mortality. Addiction, 109, 1482–1488. doi:10.1111/add.12598
   PubMed Web of Science ®Google Scholar
• Han, B., Compton, W.M., Jones, C.M., & Cai, R. (2015). Nonmedical prescription opioid use and use disorders among adulted aged 18 through 64 years in the United States, 2003–2013. JAMA, 314, 1468–1478. doi:10.1001/jama.2015.11859
   PubMed Web of Science ®Google Scholar
• Health Canada. (2018c). Supervised consumption sites: Status of applications. Retrieved form www.canada.ca/en/health-canada/services/substance-use/supervised-consumption-sites/status-application.html
   Google Scholar
• Health Canada. (2016). Canadian tobacco alcohol and drugs (CTADS): 2015 summary. Ottawa, ON: Government of Canada.
   Google Scholar
• Health Canada. (2018a). Canadian tobacco, alcohol and drugs survey (CTADS): Summary of results for 2017. Ottawa, ON: Government of Canada.
   Google Scholar
• Health Canada. (2018b). Overview of national data on opioid-related harms and deaths. Ottawa, ON: Government of Canada.
   Google Scholar
• Ialomiteanu, A. R., Hamilton, H. A., Adlaf, E. M., & Mann, R. E. (2018). CAMH monitor E-report: Substance use, mental health and well-being among Ontario adults, 1977–2017. CAMH Research Document Series No. 48. Toronto, ON: Centre for Addiction and Mental Health. Retrieved form www.camh.ca/camh-monitor
   Google Scholar
• International Narcotics Control Board. (2013). Report of the international narcotics control board for 2012. New York, NY: International Narcotics Control Board (INCB). Retrieved form https://www.incb.org/documents/Publications/AnnualReports/AR2012/AR_2012_E.pdf
   Google Scholar
• International Narcotics Control Board (INCB). (2017). Report of the international narcotics control board for 2016. New York, NY: International Narcotics Control Boards (INCB). Retrieved form https://www.incb.org/documents/Publications/AnnualReports/AR2016/English/AR2016_E_ebook.pdf
   Google Scholar
• Irvine, M.A., Buxton, J.A., Otterstatter, M., Balshaw, R., Gustafson, R., Tyndall, M., … Coombs, D. (2018). Distribution of take-home opioid antagonist kits during a synthetic opioid epidemic in British Columbia, Canada: A modelling study. The Lancet Public Health, 3, e218–e225. doi:10.1016/S2468-2667(18)30044-6
   PubMed Web of Science ®Google Scholar
• Karamouzian, M., Dohoo, C., Forsting, S., McNeil, R., Kerr, T., & Lysyshyn, M. (2018). Evaluation of a fentanyl drug checking service for clients of a supervised injection facility, Vancouver, Canada. Harm Reduction Journal, 15, 46. doi:10.1186/s12954-018-0252-8
   PubMed Web of Science ®Google Scholar
• Kerr, T., Mitra, S., Kennedy, M.C., & McNeil, R. (2017). Supervised injection facilities in Canada: Past, present, and future. Harm Reduction Journal, 14, 28. doi:10.1186/s12954-017-0154-1
   PubMed Web of Science ®Google Scholar
• Kolodny, A., Courtwright, D.T., Hwang, C.S., Kreiner, P., Eadie, J.L., Clark, T.W., & Alexander, G.C. (2015). The prescription opioid and heroin crisis: A public health approach to an epidemic of addiction. Annual Review of Public Health, 36, 559–574. doi:10.1146/annurev-publhealth-031914-122957
   PubMed Web of Science ®Google Scholar
• Montaner, J.S.G., Lima, V.D., Harrigan, P.R., Lourenço, L., Yip, B., Nosyk, B., … Kendall, P. (2014). Expansion of HAART coverage is associated with sustained decreases in HIV/AIDS morbidity, mortality and HIV transmission: The “HIV Treatment as Prevention” experience in a Canadian setting. PLoS One, 9, e87872. doi:10.1371/journal.pone.0087872
   PubMed Web of Science ®Google Scholar
• Murphy, Y., Goldner, E.M., & Fischer, B. (2015). Prescription opioid use, harms and interventions in Canada: A review update of new developments and findings since 2010. Pain Physician, 18, E605–E614. Retrieved from https://pdfs.semanticscholar.org/4feb/8b2d4c85af5a4163f25c17588eb1878d6d98.pdf
   PubMed Web of Science ®Google Scholar
• Oviedo-Joekes, E., Marchand, K., Lock, K., MacDonald, S., Guh, D., & Schechter, M.T. (2015). The SALOME Study: Recruitment experiences in a clinical trial offering in jectable diacetylmorphine and hydromorphone for opioid dependency. Substance Abuse Treatment, Prevention, and Policy, 10, 3. doi:10.1186/1747-597X-10-3
   PubMed Web of Science ®Google Scholar
• Paulozzi, L.J., Mack, K.A., & Hockenberry, J. (2014). Vital signs: Variation among states in prescribing of opioid pain relievers and benzodiazepines-United States, 2012. Morbidity Mortality Weekly Report, 63, 563–568. Retrieved from https://www.cdc.gov/mmwr/preview/mmwrhtml/mm6326a2.htm
   PubMed Web of Science ®Google Scholar
• Redelmeier, D.A., & Tien, H.C. (2014). Medical interventions to reduce motor vehicle collisions. CMAJ, 186, 188–124. doi:10.1503/cmaj.122001
   Web of Science ®Google Scholar
• Scholl, L., Seth, P., Kariisa, M., WilsonN., & Baldwin, G. (2019). Drug and opioid-involved overdose deaths – United States, 2013–2017. Atlanta, USA. Retrieved form https://www.cdc.gov/mmwr/volumes/67/wr/mm675152e1.htm?s_cid=mm675152e1_w
   Google Scholar
• Socias, M.E., & Wood, E. (2017). Epidemics of deaths from fentanyl overdose. BMJ, 28, j4355. doi:bmj.k3207/bmj.k3207.
   Google Scholar
• Spooner, L., Fernandes, K., Martins, D., Juurlink, D., Mamdani, M., Paterson, J.M., … Gomes, T. (2016). High-dose opioid prescribing and opioid-related hospitalization: A population-based study. PLoS One, 11, e0167479. doi:10.1371/journal.pone.0167479
   PubMed Web of Science ®Google Scholar
• Ye, X., Sutherland, J., Henry, B., Tyndall, M., & Kendall, P.R.W. (2018). Impact of drug overdose-related deaths on life expectancy at birth in British Columbia. Health Promotion & Chronic Disease Prevention in Canada: Research, Policy & Practice, 38, 248–251. doi:10.24095/hpcdp.38.6.05
   PubMed Web of Science ®Google Scholar